HealthFlex
×
  • About Us
    • Company Management
    • Meet Our Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
    • Careers
  • Technologies
    • Oncoprex® Delivery System
    • Reqorsa® Gene Therapy
    • GPX-002
  • Programs
    • Oncology
    • Diabetes
  • Clinical Trials
    • Pipeline
    • ONC-001
    • ONC-002
    • Acclaim-1
    • Acclaim-3
    • DIA-001 and DIA-002
    • Expanded Access Policy
  • Investors
    • Company Profile
    • Stock Information
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Downloads
    • Events
  • News
    • Press Releases
    • Blog Posts
    • Media Coverage
    • Videos
  • Contact
Tony S.K. Mok, MD, FRCP

Tony S.K. Mok, MD, FRCP

SAB Board Member

Tony S.K. Mok, BMSc, MD, FRCPC, FHKCP, FHKAM (Medicine), is a professor in the Department of Clinical Oncology at the Chinese University of Hong Kong in Prince of Wales Hospital in Hong Kong. Dr. Mok formerly served as President of the International Association for the Study of Lung Cancer (IASLC), Vice-Secretary General of the Chinese Society of Clinical Oncology (CSCO), and Co-Founder of the Lung Cancer Research Group, a multicenter organization serving the Asian-Pacific region.

Achievements

  • Past President of International Association of the Study of Lung Cancer (IASLC).
  • Chairman, Department of Clinical Oncology; Professor of Clinical Oncology, Chinese University Hong Kong

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

(877) 774-GNPX (4679)

3300 Bee Cave Road, Suite 650-227 Austin, TX 78746

Quick Links

  • About Us
  • Clinical Trials
  • Investors
  • Downloads
  • Press Releases
  • X
  • Facebook
  • LinkedIn

Latest News

  • Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer Apr 30
  • Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Apr 28
  • Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Apr 22
  • Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy Apr 21
Designed and Secured by Barsec
Copyright ©2026 all rights reserved.
Home - Privacy Policy - Terms of Use